SCA
SPRY icon

Southpoint Capital Advisors’s ARS Pharmaceuticals SPRY Stock Holding History

Southpoint Capital Advisors’s Portfolio SPRY Stock Details SPRY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-1,500,000
Closed -$17.5M – 52
2025
Q4 		$17.5M Hold
1,500,000
– – 0.41% 36
2025
Q3 		$15.1M Sell
1,500,000
-209,069
-12% -$3M 0.4% 38
2025
Q2 		$29.8M Buy
+1,709,069
New +$24.7M 0.75% 34

Other funds holding SPRY

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Southpoint Capital Advisors's SPRY Position: Q1 2026 in Review

Southpoint Capital Advisors sold out of ARS Pharmaceuticals (SPRY) in Q1 2026, closing a stake of 1,500,000 shares — an estimated $17.5M sold.

Southpoint Capital Advisors first reported a position in SPRY in Q2 2025 and held it in 3 quarters. The position peaked at $29.8M in Q2 2025. 202 funds tracked by Wall St. Rank hold SPRY as of Q1 2026.

  • Southpoint Capital Advisors reported no remaining ARS Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Southpoint Capital Advisors sold 1,500,000 ARS Pharmaceuticals shares in Q1 2026, an estimated $17.5M.
  • Southpoint Capital Advisors first reported a position in ARS Pharmaceuticals in Q2 2025 and held it in 3 quarters.
  • Southpoint Capital Advisors's ARS Pharmaceuticals position peaked at $29.8M in Q2 2025.
  • 202 funds tracked by Wall St. Rank held ARS Pharmaceuticals as of Q1 2026.

Based on Southpoint Capital Advisors's 13F filing for Q1 2026, filed 15 May 2026.